#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	5298	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2268	668.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1444	1444	C	748	C,G	685,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8486	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4011	633.0	0	.	n	.	0	T695C	SNP	695	695	T	1289	1289	C	676	C,T	601,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8486	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4011	633.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1931	1931	A	790	A	736	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8486	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4011	633.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2565	2565	C	747	C	691	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8486	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4011	633.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2639	2639	A	772	A,C	702,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8486	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4011	633.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3191	3191	C	730	C,A,T	650,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	814	folP	852	852	100.0	folP.l15.c4.ctg.1	2157	113.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1290	1292	AGC	176;177;177	A;G;C	155;157;157	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1624	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4031	120.9	1	SNP	p	S91F	0	.	.	271	273	TCC	909	911	TCC	133;132;130	T;C;C	120;123;120	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1624	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4031	120.9	1	SNP	p	D95N	0	.	.	283	285	GAC	921	923	GAC	127;128;129	G,C;A;C	119,1;118;118	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1624	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	4031	120.9	1	SNP	p	D95G	0	.	.	283	285	GAC	921	923	GAC	127;128;129	G,C;A;C	119,1;118;118	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	820	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1786	137.3	0	.	p	.	0	A40P	NONSYN	118	120	GCC	705	707	CCC	201;200;200	C;C;C	181;185;183	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	820	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1786	137.3	1	SNP	p	G45D	0	.	.	133	135	GGC	720	722	GGC	204;203;203	G;G,A;C	186;184,1;187	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1784	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3514	152.1	1	SNP	p	D86N	0	.	.	256	258	GAC	879	881	GAC	188;187;187	G;A;C	169;162;166	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1784	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3514	152.1	1	SNP	p	S87I	0	.	.	259	261	AGT	882	884	AGT	187;188;188	A,C;G;T	159,1;170;162	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1784	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3514	152.1	1	SNP	p	S87W	0	.	.	259	261	AGT	882	884	AGT	187;188;188	A,C;G;T	159,1;170;162	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1784	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3514	152.1	1	SNP	p	S87R	0	.	.	259	261	AGT	882	884	AGT	187;188;188	A,C;G;T	159,1;170;162	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1784	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3514	152.1	1	SNP	p	S88P	0	.	.	262	264	TCC	885	887	TCC	189;191;190	T,G;C;C	162,1;173;176	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1588	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3232	147.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1837	1839	GGC	179;178;176	G;G,C;C	161;160,1;159	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1499	1501	GCA	173;175;175	G;C,A;A	158;159,1;161	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1502	1504	ATC	174;174;175	A;T,G,C;C	160;158,1,1;163	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1514	1516	GTG	178;178;180	G;T;G,A	165;155;165,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1514	1516	GTG	178;178;180	G;T;G,A	165;155;165,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2018	2020	ACC	130;130;131	A;C;C	125;124;125	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2072	2074	GCG	133;133;133	G;C;G	118;106;114	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2072	2074	GCG	133;133;133	G;C;G	118;106;114	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2195	2197	GGC	155;155;155	G;G;C	133;134;130	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2204	2206	GGC	155;155;154	G;G;C	133;134;135	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2887	132.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2222	2224	CCG	158;159;160	C,G;C;G	133,2;142;131	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1900	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3635	156.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1865	1867	CTG	183;183;183	C;T;G	161;160;166	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1026	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2310	132.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	937	937	C	171	C,T	159,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	0	.	p	.	0	E41K	NONSYN	121	123	GAA	706	708	AAA	201;201;202	A,G;A;A	183,1;185;186	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	0	.	p	.	0	F135L	NONSYN	403	405	TTT	988	990	CTT	191;189;190	C,G;T,G;T,G,C	177,2;178,2;176,2,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1012	1014	GGA	190;190;190	G;G,A;A	179;177,2;179	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1096	1098	GGT	177;178;178	G;G;T	163;167;165	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1150	1152	AGC	176;178;179	A;G,A;C,T	160;159,1;155,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1216	1216	T	157	T	143	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	1	SNP	p	G120K	0	.	.	358	360	GGT	943	945	GGT	193;193;193	G;G;T,C	182;181;174,2	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	1	SNP	p	A121N	0	.	.	361	363	GCC	946	948	GCC	193;194;194	G,A;C,A,G;C	175,1;176,2,1;184	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	932	porB1b	1035	1035	95.73	porB1b.l6.c30.ctg.1	1998	137.5	1	SNP	p	A121D	0	.	.	361	363	GCC	946	948	GCC	193;194;194	G,A;C,A,G;C	175,1;176,2,1;184	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3226	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5499	175.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2447	2449	AAT	191;192;191	A;A;T	174;175;175	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	570	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1546	110.1	1	SNP	p	V57M	1	.	.	169	171	ATG	711	713	ATG	194;194;194	A;T,C;G	180;176,1;179	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
